mezigdomide (CC-92480)

Finally, we demonstrate the ability of Mezigdomide to enhance survival outcomes from anti-BCMA CAR-T therapy in vivo. Overall, our data show that Mezigdomide treatment improves anti-myeloma T cell therapy efficacy and reduces T cell dysfunction by abrogating Ikaros-mediated upregulation of exhaustion genes.

Utilizing this workflow, we studied dose-dependent protein degradation patterns induced by pomalidomide, iberdomide, and mezigdomide. Our results indicate that mezigdomide may possess enhanced efficacy in T cells by degrading additional proteins such as IKZF2, thereby boosting anticancer immunity. Together, we developed an ultrahigh-throughput LC-MS/MS method with excellent proteome coverage and quantitation accuracy that is highly suitable for chemoproteomics screening of drug libraries.

P1/2, N=300, Active, not recruiting, Karyopharm Therapeutics Inc | Recruiting --> Active, not recruiting

P1, N=4, Terminated, Celgene | N=156 --> 4 | Active, not recruiting --> Terminated; Business objectives have changed

P1, N=25, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting

P1/2, N=44, Not yet recruiting, Centre Hospitalier Universitaire De Saint Etienne

P1/2, N=70, Not yet recruiting, Assistance Publique Hopitaux De Paris

P1, N=15, Recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026

P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Trial primary completion date: Feb 2026 --> Jul 2026

P2/3, N=322, Active, not recruiting, Celgene Corp. | Recruiting --> Active, not recruiting

P1/2, N=24, Recruiting, Celgene Corp.

P3, N=525, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting